8-K
filed July 1, 2024, 7:59 PM ET
CIK 0000887247
other material
confidence high
sentiment negative
materiality 0.75
DMK PHARMACEUTICALS Corp: M&A transaction — DMK Pharmaceuticals sells ZIMHI assets for $3.17M; entire board and CEO resign effective June 27, 2024
DMK PHARMACEUTICALS Corp
- Sold ZIMHI assets to zmi pharma inc. for $3,170,600 on May 16, 2024, approved by Bankruptcy Court.
- Chairman and CEO Ebrahim Versi resigned as director and CEO effective June 27, 2024.
- All other directors (Birndorf, Desai, Reed, J. Versi) resigned; no disagreements cited.
- General Counsel John Dorbin separated; CFO Seth Cohen named Chief Restructuring Officer.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Vickie S. Reed resigned as Director at DMK PHARMACEUTICALS Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
Additionally, Howard C. Birndorf, Meera J. Desai, Ph.D, NACD.DC, Vickie S. Reed, and Jannine C. A. Versi resigned as Directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jannine C. A. Versi resigned as Director at DMK PHARMACEUTICALS Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
Additionally, Howard C. Birndorf, Meera J. Desai, Ph.D, NACD.DC, Vickie S. Reed, and Jannine C. A. Versi resigned as Directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Meera J. Desai resigned as Director at DMK PHARMACEUTICALS Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
Additionally, Howard C. Birndorf, Meera J. Desai, Ph.D, NACD.DC, Vickie S. Reed, and Jannine C. A. Versi resigned as Directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Seth Cohen changed role as Chief Restructuring Officer at DMK PHARMACEUTICALS Corp.
- Action
- assumed the role of
- Role
- Chief Restructuring Officer
Exact text from the filing
Effective June 27, 2024, Seth Cohen, the Company’s Chief Financial officer will assume the role of Chief Restructuring Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ebrahim “Eboo” Versi resigned as Chairman of the Board at DMK PHARMACEUTICALS Corp.
- Action
- resigned
- Role
- Chairman of the Board
Exact text from the filing
Effective June 27, 2024, Ebrahim “Eboo” Versi, M.D., Ph.D. resigned as Chairman of the Board and as a Director of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John W. Dorbin, Jr. departed as General Counsel and Corporate Secretary at DMK PHARMACEUTICALS Corp.
- Action
- separated
- Role
- General Counsel and Corporate Secretary
Exact text from the filing
John W. Dorbin, Jr. was also separated from his role as General Counsel and Corporate Secretary of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Howard C. Birndorf resigned as Director at DMK PHARMACEUTICALS Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
Additionally, Howard C. Birndorf, Meera J. Desai, Ph.D, NACD.DC, Vickie S. Reed, and Jannine C. A. Versi resigned as Directors of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ebrahim “Eboo” Versi departed as Chief Executive Officer at DMK PHARMACEUTICALS Corp.
- Action
- separated
- Role
- Chief Executive Officer
Exact text from the filing
Also effective June 27, 2024, Mr. Versi was separated from his role as Chief Executive Officer of the Company
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
DMK PHARMACEUTICALS Corp completed a disposition involving zmi pharma inc. for $3,170,600 (closed 2024-05-16).
- Action
- disposition
- Counterparty
- zmi pharma inc.
- Consideration
- $3,170,600
- Closing
- 2024-05-16
Exact text from the filing
On May 16, 2024, pursuant to an agreement approved by the Bankruptcy Court, the Company sold all of its assets relating to its ZIMHI products and business to zmi pharma inc. for $3,170,600.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.